

Luton & Dunstable University Hospital
Bedfordshire Hospitals NHS Foundation Trust
Lewsey Road
Luton
LU4 0DZ

Bedford Hospital
Bedfordshire Hospitals NHS Foundation Trust
Kempston Road
Bedford
MK42 9DJ

04/01/2021

Dear Requester,

Thank you for your Freedom of Information request which was received within the Trust.

In accordance with S.1 (1) (a) of the Freedom of Information Act 2000 (FOIA), I can confirm that we do hold the information relevant to your request. FOI 270

Response from Luton and Dunstable University Hospital

How many patients were diagnosed with prostate cancer over the last 3 months? Of these, how many patients were diagnosed with metastatic prostate cancer?

We only receive information on chemotherapy prescribed so this won't include all newly diagnosed prostate cancer patients.

2. How many prostate cancer patients were treated over the last 3 months with:
 - a. Docetaxel **16**
 - b. Abiraterone **8**
 - c. Enzalutamide **68**
 - d. Cabazitaxel **2**

3. How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one? **Ovarian cancer patients are treated at Mount Vernon Hospital so not applicable to us.**

4. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with: **Ovarian cancer patients are treated at Mount Vernon Hospital not applicable to us.**

- a. Paclitaxel in combination with a platinum-based compound
- b. Platinum-based therapy alone (cisplatin or carboplatin)
- c. Bevacizumab in combination with paclitaxel and carboplatin
- d. Olaparib
- e. Niraparib
- f. Rucaparib

5. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?

Ovarian cancer patients are treated at Mount Vernon Hospital not applicable to us.

6. Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received?

- a. Olaparib for 1st line maintenance
- b. Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance

Ovarian cancer patients are treated at Mount Vernon Hospital so not applicable to us.

Response from Bedford Hospital

1. How many patients were diagnosed with prostate cancer over the last 3 months? Of these, how many patients were diagnosed with metastatic prostate cancer?

35 prostate diagnosed between 01-09 & 30-11, 0 diagnosed with metastatic prostate cancer

2. How many prostate cancer patients were treated over the last 3 months with:

- a. Docetaxel **0-5**
- b. Abiraterone **9**
- c. Enzalutamide **34**
- d. Cabazitaxel **0**

2. How many prostate cancer patients were treated over the last 3 months with:

- a. Docetaxel **0-5**
- b. Abiraterone **9**
- c. Enzalutamide **35**
- d. Cabazitaxel **0**

3. How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?

Ovarian patients are not seen at Bedford and are sent to Addenbrookes Hospital

4. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with:

- a. Paclitaxel in combination with a platinum-based compound **0-5**
- b. Platinum-based therapy alone (cisplatin or carboplatin) **0-5**
- c. Bevacizumab in combination with paclitaxel and carboplatin **0-5**
- d. Olaparib **0-5**
- e. Niraparib **0-5**
- f. Rucaparib **0**

5. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?

Ovarian patients are not seen at Bedford and are sent to Addenbrookes Hospital

6. Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received

- a. Olaparib for 1st line maintenance **0-5**
- b. Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance **0-5**

6. Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received

- a. Olaparib for 1st line maintenance **0-5**
- b. Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance **0-5**

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to:

Luton & Dunstable University Hospital
Bedfordshire Hospitals NHS Foundation Trust
Lewsey Road
Luton
LU4 0DZ

Bedford Hospital
Bedfordshire Hospitals NHS Foundation Trust
Kempston Road
Bedford
MK42 9DJ

Or by emailing bhn-tr.foibedfordshirehospitals@nhs.net. This option is available to you for up to three calendar months from the date your response was issued.

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF
www.ico.org.uk

Yours sincerely,

IG/FOI Coordinator

Bedford Hospital, Kempston, Bedford
MK42 9DJ

Luton & Dunstable Hospital
Lewsey Road, Luton
LU4 0DZ